Artificial intelligence (AI) software developer Medo.ai has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Automated Real-time Intelligent Assistant (ARIA), an AI software application for detecting hip dysplasia on ultrasound exams in infants.
ARIA automatically reviews hip ultrasound images, selects the optimal image to calculate standard measurements, and assists clinicians in classifying and diagnosing hips as normal or dysplastic, according to the company. Medo.ai said that its AI and 3D-based technology has been shown to be as accurate as expert radiologists in diagnosing hip dysplasia and that scans from its technology have been found to be easier to acquire and interpret than those from conventional methods.
The company, with offices in Canada and Singapore, said that its goal is to have every infant scanned for hip dysplasia near birth. In addition, it's currently developing its AI-augmented ultrasound for use in many other clinical problems, according to the firm.
